615-P: A Novel Lipid-Lowering Drug Pemafibrate Enhances Effects of Statins in Serum Lipids in Japanese Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 615-P ◽  
Author(s):  
MASATAKA KUSUNOKI ◽  
YUKIE NATSUME ◽  
YOSHIHARU OSHIDA ◽  
TETSURO MIYATA
Keyword(s):  
Type 2 Diabetes ◽  
Serum Lipids ◽  
Japanese Patients ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lowering Drug

A large remaining potential in lipid‐lowering drug treatment in the type 2 diabetes population – a Danish nationwide cohort study

2021 ◽  
Author(s):  
Hanan Amadid ◽  
Pernille F. Rønn ◽  
Maria BN. Dunbar ◽  
Jakob S. Knudsen ◽  
Bendix Carstensen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Drug Treatment ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lowering Drug

137-OR: Trends in Lipid Levels Relative to Lipid-Lowering Drug Use among Danish Type 2 Diabetes Subjects

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 137-OR
Author(s):  
HANAN AMADID ◽  
MARIA BEKKER-NIELSEN DUNBAR ◽  
PERNILLE F. RØNN ◽  
JAKOB S. KNUDSEN ◽  
BENDIX CARSTENSEN ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Drug Use ◽  
Lipid Lowering ◽  
Lipid Levels ◽  
Lipid Lowering Drug ◽  
Lowering Drug

scholarly journals Use of electronic patient data overview with alerts in primary care increases prescribing of lipid-lowering medications in patients with type 2 diabetes

Diabetologia ◽  
2021 ◽  
Author(s):  
Morten H. Charles ◽  
Janus L. Thomsen ◽  
Bo Christensen ◽  
Ryan Pulleyblank ◽  
Line P. Kongstad ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Diabetes Duration ◽  
Lipid Lowering ◽  
Control Group ◽  
Lipid Lowering Drugs ◽  
Lipid Lowering Drug ◽  
Level Of Use ◽  
Lowering Drug ◽  
High Level

Abstract Aims/hypothesis We aimed to assess whether general practices (GPs) using an electronic disease management program (DMP) with population overviews, including alerts when patients failed to receive guideline-recommended prescription medications, increased prescriptions of lipid-lowering drugs for patients with type 2 diabetes with no history of lipid-lowering treatment. Methods This observational study included 165 GPs that reached a high level of use of the DMP in 2012 and a control group of 135 GPs who reached a high level of use in 2013 and, hence, who were less exposed to the DMP throughout 2012. A binary measure for having been prescribed and filled lipid-lowering drugs at any time within a 12-month exposure period was derived for all patients with type 2 diabetes who did not receive a prescription for lipid-lowering drugs in the baseline year prior to the study period (i.e. 2011). Results were derived using ORs from multivariate logistic regression analyses. Subgroup stratification based on age, sex, diabetes duration, deprivation status and Charlson Comorbidity Index (CCI) score was conducted and assessed. Placebo tests were carried out to assess bias from selection to treatment. Results Patients who did not receive a prescription of lipid-lowering drugs in the year prior to being listed with GPs that used the DMP had statistically significant greater odds of receiving a prescription of lipid-lowering medications when compared with individuals who attended control GPs (OR 1.23 [95% CI 1.09, 1.38]). When the analysis period was shifted back by 2 years, no significant differences in lipid-lowering drug prescription between the two groups were found to occur, which indicates that these results were not driven by selection bias. Subgroup analyses showed that the increase in lipid-lowering drug prescriptions was primarily driven by changes among male participants (OR 1.32 [95% CI 1.12, 1.54]), patients aged 60–70 years (OR 1.40 [95% CI 1.13, 1.74]), patients with a diabetes duration of ≤5 years (OR 1.33 [95% CI 1.13, 1.56]), non-deprived patients (OR 1.25 [95% CI 1.08, 1.45]) and patients without comorbidities (CCI score = 0; OR 1.27 [95% CI 1.11, 1.45]). Conclusions/interpretation Access to population overviews using a DMP with alerts of clinical performance measures with regard to adhering to guideline-recommended prescription of medications can increase GP prescriptions of lipid-lowering drugs. Graphical abstract

The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes

Drug Research ◽  
2015 ◽  
Vol 66 (01) ◽  
pp. 18-22 ◽  
Author(s):  
M. Kusunoki ◽  
D. Sato ◽  
T. Nakamura ◽  
Y. Oshida ◽  
H. Tsutsui ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Serum Lipids ◽  
Hemoglobin A1c ◽  
Japanese Patients ◽  
Beneficial Effects

Abstract P047: Improved Clinical Outcomes Associated with Dual-Goal (HbA1c and LDL-C) Achievement in Newly Diagnosed Type 2 Diabetes Mellitus

Circulation ◽  
2013 ◽  
Vol 127 (suppl_12) ◽  
Author(s):  
Lizheng Shi ◽  
Xin Ye ◽  
Mei Lu ◽  
Eric Q Wu ◽  
Hari Sharma ◽  
...  
Keyword(s):  
Index Date ◽  
Microvascular Complications ◽  
Goal Achievement ◽  
Lipid Lowering ◽  
Newly Diagnosed ◽  
Factors Associated ◽  
Lipid Lowering Drug ◽  
Clinical Benefits ◽  
Lowering Drug

Background: Compared with studies on achieving a single goal of either glycated hemoglobin (HbA1c) or low-density lipoprotein cholesterol (LDL-C) in type 2 diabetes mellitus (T2DM), the clinical benefits of dual-goal achievement (LDL-C<100 mg/dl and HbA1c<7%) are not well documented. This study investigated factors and clinical benefits associated with dual-goal achievement in newly diagnosed T2DM patients. Methods: Newly diagnosed adult T2DM patients with ≥2 measures of LDL-C and HbA1c were identified in the Veterans Integrated Services Network 16 data warehouse (01/2004-06/2010). A logistic regression model was used to identify factors associated with dual-goal achievement during 7-12 months following the index date (first HbA1c recorded within three months of the first T2DM diagnosis). Factors included demographics and 0-6 month dual-goal achievement, as well as diabetes-related comorbidities, medications, surgeries, and healthcare utilization, all measured during the 1-year period surrounding the index date. Multivariate Cox proportional hazards models were used to assess the association between time-varying goal achievement status and post-index date clinical outcomes, including microvascular complications (retinopathy, nephropathy, and neuropathy), cardiovascular-related complications (cardiovascular death, stroke, or myocardial infarction) and acute coronary syndromes (ACS). Results: A total of 16,829 T2DM patients were included in the study. Factors associated with an increased likelihood of dual-goal achievement include older age, higher Charlson Comorbidity Index (CCI), prior dual-goal achievement, diagnosis of ketoacidosis or hypersmolarity, and lipid-lowering drug use. Conversely, patients with prior diagnoses of retinopathy, neuropathy, and congestive heart failure, as well as prior insulin use were less likely to achieve both goals. Compared with failure to achieve either goal, achieving only LDL-C goal was associated with a lower risk of cardiovascular-related complications (HR:0.76; 95% CI:0.71-0.81) and ACS (HR:0.76; 95% CI:0.67-0.86), while achieving only HbA1C goal was associated with a lower risk of microvascular complications (HR:0.73; 95% CI:0.71-0.74), cardiovascular-related complications (HR:0.80; 95% CI:0.74-0.87) and ACS (HR:0.66; 95% CI:0.60-0.72). Dual-goal achievement was associated with additional reduction in risk of microvascular complications (HR: 0.69; 95% CI: 0.63-0.76) vs. only LDL-C goal achievement, but had similar risk to achieving HbA1c goal alone. Conclusions: Older age, higher CCI, prior dual-goal achievement, and lipid-lowering drug use were associated with a greater likelihood of dual-goal achievement. Dual-goal achievement in newly diagnosed T2DM patients is associated with decreased risks of microvascular complications than those with only LDL-C goal achievement.

Comparative hypolipidemic efficacy of homeopathic mother tincture Allium Sativa Q, Curcuma Longa Q and statin in normal and cholesterol fed rabbits

2019 ◽  
Author(s):  
Khalid Mahmood Anjum ◽  
Fayyaz Rasool Rasool ◽  
Ehsan Mehmood Bhatti ◽  
Samina Liaquat ◽  
Muhammad Zubair Yousaf ◽  
...  
Keyword(s):  
High Fat Diet ◽  
Serum Lipids ◽  
Curcuma Longa ◽  
Lipid Lowering ◽  
High Density Lipoproteins ◽  
Comparative Efficacy ◽  
Statin Group ◽  
Lipid Lowering Drug ◽  
Mother Tincture ◽  
Lowering Drug

Although, lipid lowering drugs regulate the blood serum lipids, they have several reported side effects. Therefore, a substance that is less toxic and yet effective would be beneficial. Here, we compared the antihypercholesterolemic effects of combinations of homeopathic mother tincture (HMT) Allium sativa Q (garlic) and Curcuma longa Q (turmeric), with standard lipid lowering drug statin. For experimentation, a total of 20 rabbits were recruited and divided into four groups with five rabbits (n = 5). Normal saline (NS) group served as control; second group served as high fat diet (HFD) group, third group received Allium sativa Q (garlic) and Curcuma longa Q (turmeric) and HFD (T and G group) while the fourth group received statin and HFD (statin group). At the end of the 8th week, blood was collected to analyze the comparative efficacy of Allium sativa Q, Curcuma longa Q and statin on total cholesterol (TC), low density lipoproteins (LDL), high density lipoproteins (HDL) and triglyceride (TG). Various parameters measured (mg/dl) in HFD rabbits were, TC (291.76±2.2), LDL (244.20±8.3) and triglycerides (243.79±4.3) increased significantly and HDL (32.19±3.3) was reduced to an alarming level as compared to the NS group after eight weeks. TC, LDL and triglycerides level reduced significantly in Tand G group while the HDL level increased significantly as compared to HFD. In statin group, TC (148.37±1.2), LDL (76.32 ±3.4) and TG (104.33 ±8.9) decreased while HDL increased (p LESS than 0.05) as compared to the HFD after eight weeks. It was therefore concluded that that homeopathic medicine Allium sativa Q and Curcuma longa Q is equally good like statin and can safely be used to regulate the circulating serum lipid profile

Sign in / Sign up

Export Citation Format

Share Document